Vertex ended work on the islet cell-device combo in late March after phase 1/2 trial findings suggested that it would be unlikely to trigger sufficient levels of insulin production.

Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain ...

Vertex reported Q1 revenue and earnings that fell well short of what most investors were anticipating. Higher costs were primarily responsible for the hit to earnings. Despite the headwinds ...

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) have been very resilient in the last six months. There was that brief trip to just below $400 per share in December after suzetrigine (Journavx ...

Vertex Pharmaceuticals reported disappointing first-quarter earnings yesterday. It saw weaker-than-expected sales of its cystic fibrosis drugs and little or no contributions from a gene therapy ...

It compiled a Quality Improvement Programme (QIP) study using data from 149 emergency departments involving 24,865 patients. Among patients over 75, the research found insufficient screening for ...

Its Quality Improvement Programme (QIP) study received data from 149 emergency departments involving 24,865 patients. Among patients over 75, the research found insufficient screening for three ...

Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug. This biotech stock should still generate exceptional returns over the ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...